In contrast, high expression of CB1 and CB2 indicates longer disease-free survival in patients with hepatocellular carcinoma [47], while a lower expression of CB1 is correlated with a lower survival in patients with pancreatic ductal carcinoma [48]. This evidence concerns the gene CNR2 and hepatocellular carcinoma.